Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

RCT (n=3730, class II-IV heart failure, ejection fraction ≤40%) found empagliflozin in addition to standard treatments reduced risk & total number of inpatient and outpatient worsening heart failure events (415 vs 519 patients, respectively; HR 0.76, 95% CI,0.67-0.87;p<0.0001).

Circulation